OYST - Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study

Oyster Point Pharma (OYST) announces enrollment of the first subject in the OLYMPIA Phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy ((NK)), a rare disease characterized by decreased corneal sensitivity and poor corneal healing.The study is a multicenter, randomized, double-masked, placebo-controlled trial to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in subjects with Mackie’s Classification Stage 1 NK.The pre-specified primary endpoint of the trial, which is expected to enroll about 100 subjects at ~18 U.S. sites, will be the percentage of subjects who achieve complete resolution of fluorescein corneal staining at Day 56.  Oyster Point had formed a research collaboration with Adaptive Phage Therapeutics ((APT)) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases, earlier this month.

For further details see:

Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study